Cantor Fitzgerald Has Positive View of RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for shares of Arcus Biosciences in a report issued on Thursday, August 7th. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($3.69) per share for the year, up from their previous forecast of ($4.52). The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Cantor Fitzgerald also issued estimates for Arcus Biosciences’ FY2026 earnings at ($4.22) EPS.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The company had revenue of $160.00 million for the quarter, compared to analyst estimates of $32.86 million. During the same period in the prior year, the company earned ($1.02) earnings per share. The firm’s revenue was up 310.3% on a year-over-year basis.

A number of other research analysts have also weighed in on RCUS. Morgan Stanley decreased their price target on shares of Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Wall Street Zen raised shares of Arcus Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Wells Fargo & Company decreased their price target on shares of Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Finally, The Goldman Sachs Group decreased their price target on shares of Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

Arcus Biosciences Trading Up 1.4%

RCUS stock opened at $9.19 on Monday. The company’s 50-day simple moving average is $9.15 and its 200-day simple moving average is $9.38. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $18.98. The firm has a market cap of $977.56 million, a P/E ratio of -2.90 and a beta of 0.89.

Hedge Funds Weigh In On Arcus Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in shares of Arcus Biosciences during the 4th quarter worth $507,000. Wells Fargo & Company MN lifted its position in shares of Arcus Biosciences by 105.9% during the 4th quarter. Wells Fargo & Company MN now owns 38,618 shares of the company’s stock worth $575,000 after purchasing an additional 19,865 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Arcus Biosciences by 187.7% during the 4th quarter. Russell Investments Group Ltd. now owns 29,953 shares of the company’s stock worth $446,000 after purchasing an additional 19,543 shares during the last quarter. Invesco Ltd. lifted its position in shares of Arcus Biosciences by 21.4% during the 4th quarter. Invesco Ltd. now owns 203,987 shares of the company’s stock worth $3,037,000 after purchasing an additional 35,905 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Arcus Biosciences during the 4th quarter worth $531,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.